# Influenza Vaccine To Prevent Adverse Vascular Events:Pilot

Study · id `cardio:ct-nct01945268` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01945268](<https://clinicaltrials.gov/study/NCT01945268>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01945268

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

## Technical summary

Registry record NCT01945268. Randomized; quadruple masking; primary purpose treatment. Start 2015-04 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 107 participants (enrolled count; ClinicalTrials.gov record NCT01945268, source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)
- Start date: 2015-04 (registry gives no type) (ClinicalTrials.gov record NCT01945268, source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT01945268, source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT01945268, source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)
- Countries: Mozambique; Philippines; Uganda (ClinicalTrials.gov record NCT01945268, source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01945268-2018-10-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Influenza Vaccine To Prevent Adverse Vascular Events:Pilot
- Acronym: IVVE:Pilot
- Condition: Heart Failure
- Intervention (Drug): inactivated trivalent influenza vaccine
- Intervention (Other): Sterile saline
- Lead sponsor: McMaster University
- Lead sponsor class: OTHER
- Collaborator: Population Health Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: McMaster University (`cardio:org-mcmaster-university`)
- Registry lists this organization as a collaborator: Population Health Research Institute (`cardio:org-population-health-research-institute`)

## Provenance

Content hash: fa14facb58d99117dd646a5c5cad1b054d67db0108d8d6fa511b3a0e9e780e2b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
